NovaThera and Pharming completed proof-of-concept studies designed to develop a new generation of bioactive materials. These materials are based on a fusion of the two companies’ technologies —TheraGlass™ (a nonceramic glass) and recombinant human proteins.
TheraGlass-rH (TheraGlass with recombinant human proteins) has the potential to extend the therapeutic potential from transgenic technologies into the arena of medical devices and materials technologies, the companies report. The new materials can be used for the localized delivery of therapeutic proteins and for developing devices, such as stents and catheters.
The initial focus is on stents containing materials able to release recombinant human proteins, such as collagen, fibrinogen, lactoferrin, and C1 inhibitor.